A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR -mutated, MET -amplified advanced non-small-cell lung cancer

The objective response rates in EGFR T790M-negative, −positive, and -unknown patients were 52% (12/23), 9% (2/23), and 40% (2/5), respectively. Savolitinib 600 mg plus gefitinib 250 mg once daily had an acceptable safety profile and d emonstrated promising antitumor activity in EGFRm, MET-amplified advanced NSCLC patients who had disease progression on EGFR-TKIs. NCT02374645, Date of registration: March 2nd 2015.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research